Merck KGaA Patient Finder Suitability Analysis

1. TEPMETKO (Tepotinib) - METex14 NSCLC

Tier 1 | Fit Score: 9/10 | Market Expansion Play

Key Insight

Testing Gap = Market Expansion: Fewer than 50% of advanced NSCLC patients receive the comprehensive NGS testing needed to identify METex14 mutations. This leaves 3,500-4,700 eligible US patients annually without access to targeted therapy—they default to suboptimal chemotherapy instead.

Market Numbers

• USA: 235,000 annual NSCLC cases → 7,050-9,400 METex14 cases (3-4%) → 50% testing gap = 2,100-2,800 undiagnosed drug-addressable
• DACH: 63,265 NSCLC cases → 451-602 undiagnosed drug-addressable (40% testing gap, better than USA)
• Rest of World: 3,000-4,000 undiagnosed drug-addressable (focus: EU ex-DACH, Japan, Canada, Australia)
• Current Market: $142M globally (Tepmetko + Tabrecta); Growth Potential: $300-400M by 2030 if testing reaches 80%+

Clinical & Diagnostic Profile

• Symptoms: Persistent cough (85%), hemoptysis (25-30%), dyspnea (60%), weight loss (40%); often asymptomatic until advanced
• Diagnostic Delay: Testing gap is primary barrier (not symptom-to-diagnosis delay); NGS results take 7-21 days when ordered
• Common Misdiagnoses: Pneumonia, COPD exacerbation, asthma, tuberculosis
• Ada Surface Ability: 9/10 — Respiratory symptoms well-captured; two intervention points: (1) Pre-diagnosis: Flag for low-dose CT screening, (2) Post-diagnosis: Ensure NGS testing before chemo

Commercial Signals

• Launch: FDA traditional approval Feb 2024 (accelerated 2021); revenue ramping slowly due to testing gap
• Competition: Tabrecta (Novartis) has 52% market share; Tepmetko differentiates with once-daily dosing vs BID
• Company Motivation: 9/10 — Oncology is strategic priority post-Mavenclad cliff; CEO Kai Beckmann prioritizes growth businesses
• Partnership Fit: Merck seeks "diagnostic and patient identification platforms" — testing advocacy aligns perfectly

2. ERBITUX (Cetuximab) - Head & Neck Cancer

Tier 1 | Fit Score: 9/10 | Severe Diagnostic Delay

Key Insight

8+ Month Diagnostic Delay: Head and neck cancer symptoms (persistent sore throat, hoarseness, neck lumps) get dismissed as infections, leading to median 8+ month delays (4-12 weeks even in developed markets). 65% of patients delayed >3 months. By the time of diagnosis, 30% present at advanced stages.

Market Numbers

• USA: 55,000 annual HNC cases → 13,200-14,850 Erbitux-eligible (advanced/platinum-resistant) → 30% late-stage presentation due to delay = 3,300-3,500 undiagnosed drug-addressable
• DACH: 12,000-15,000 HNC cases → 860-1,350 undiagnosed drug-addressable
• Rest of World: 7,750-8,750 undiagnosed drug-addressable
• Revenue: Erbitux global €1.2B (2024), +15.7% growth despite biosimilars; USA ~$420M

Clinical & Diagnostic Profile

• Symptoms: Persistent sore throat >3 weeks (60%), hoarseness (40%), dysphagia (50%), neck mass (50%), otalgia (referred ear pain, 30%)
• Diagnostic Delay: 8+ months (underserved regions), 4-12 weeks (developed); misattributed to pharyngitis, laryngitis, GERD, dental issues
• Common Misdiagnoses: Multiple antibiotic courses for "tonsillitis," voice overuse (hoarseness), dental abscess (mouth ulcer)
• Ada Surface Ability: 9/10 — "Persistent sore throat >3 weeks" is textbook red flag; throat/voice/swallowing symptoms are Ada's strength

Commercial Signals

• Performance: +15.7% growth (2024) despite core patents expired (US 2016, EU 2014); biosimilars in India, China, Russia
• Strategy: Volume growth (finding more patients) offsets biosimilar price erosion
• Company Motivation: 8/10 — Mature product, but patient finding = differentiation vs biosimilars ("We find patients early and save lives")
• Competition: Keytruda gaining share in first-line; Vectibix (Amgen) splits EGFR market 50/50

3. BAVENCIO (Avelumab) - Urothelial Carcinoma

Tier 1 | Fit Score: 8/10 | Highest Per-Patient Economics

Key Insight

UTI Misdiagnosis = Advanced Stage: Bladder cancer presents with hematuria and urinary symptoms that mimic UTIs. Patients receive 2-4 antibiotic courses before cystoscopy, creating 78-82 day delays. This increases odds of muscle-invasive or metastatic disease by 28-42%, pushing patients into the advanced Bavencio-eligible population.

Market Numbers

• USA: 82,000 annual bladder cancer cases → 9,840 advanced UC Bavencio-eligible (post-platinum maintenance) → 15-20% UTI delay = 1,260-1,600 undiagnosed drug-addressable
• DACH: 9,600-12,000 bladder cancer → 170-220 undiagnosed drug-addressable
• Rest of World: 1,800 undiagnosed drug-addressable
• Revenue: Bavencio estimated $1-2B globally (not broken out separately); UC maintenance is key growth driver

Clinical & Diagnostic Profile

• Symptoms: Hematuria (gross/microscopic, 80-90%), dysuria (30%), urinary frequency/urgency (40%), pelvic pain (20%)
• Diagnostic Delay: 78-82 days symptoms-to-surgery; multiple antibiotic courses before imaging
• Common Misdiagnoses: UTI (urinary symptoms + hematuria), kidney stones (hematuria), menstruation (women), prostatitis (men)
• Ada Surface Ability: 8/10 — Hematuria and "recurrent UTI" pattern easily captured; key value is flagging UTI without positive culture for cystoscopy

Commercial Signals

• UC Maintenance: FDA-approved first-line maintenance post-platinum chemo; real-world evidence supports durable responses
• Competition: EXTREME — Keytruda ($25B) and Opdivo ($8B) dominate; Bavencio's niche is UC maintenance defense
• Company Motivation: 7/10 — Niche differentiation strategy; patient finding aligns with defending UC maintenance vs Keytruda
• Economics: Highest per-patient revenue in portfolio ($1.08M) justifies $86-130K PF fees

4. BAVENCIO (Avelumab) - Merkel Cell Carcinoma

Tier 2 | Fit Score: 8/10 | Ultra-Rare, High-Value

Key Insight

The Great Masquerader: MCC appears as innocuous skin nodules, mistaken for cysts or infections. <1% correctly suspected pre-biopsy, with >3 month diagnostic delays while aggressive cancer spreads lymphatically. 5-year survival <20% at advanced stages.

Market Numbers

• USA: ~3,000 annual MCC cases → 1,650 metastatic/locally advanced → 20% delay = 300-400 undiagnosed drug-addressable
• DACH: ~460 MCC cases → 50 undiagnosed drug-addressable
• Prevalence: 0.7 per 100,000 (US), higher in elderly (>70%), immunocompromised, sun-exposed regions

Clinical & Diagnostic Profile

• Symptoms: Rapidly growing, painless skin nodule (80%), red/purple/flesh-colored, firm, sun-exposed areas (head/neck 45-49%)
• Diagnostic Delay: >3 months nodule-to-biopsy; often "watch and wait" before dermatology referral
• Common Misdiagnoses: Epidermoid cyst, lipoma, abscess, seborrheic keratosis, basal cell carcinoma
• Ada Surface Ability: 6/10 — Skin lesion assessment challenging without visual AI; risk factors (age >70, immunosuppressed) help

Strategic Value

• Company Motivation: 7/10 — Orphan drug, limited market size, but demonstrates rare disease expertise (aligns with SpringWorks acquisition narrative)
• First-Mover: Bavencio was first checkpoint inhibitor approved for MCC (2017); Keytruda approved 2018 but no clear efficacy advantage

5. ERBITUX (Cetuximab) - Colorectal Cancer

Tier 2 | Fit Score: 7/10 | Screening Gaps

Key Insight

Post-Colonoscopy Underdiagnosis: Colonoscopy screening misses 2.5-7.7% of CRC cases (right-sided lesions, polyp morphology). Symptomatic patients wait 34-60 days for diagnosis while rectal bleeding gets attributed to hemorrhoids or IBS.

Market Numbers

• USA: 160,000 annual CRC cases → 18,400-24,150 metastatic RAS wild-type → 3-5% underdiagnosis = 400-650 undiagnosed Erbitux-eligible
• RAS Wild-Type: 50-65% of metastatic CRC (EGFR therapy eligible)

Clinical & Diagnostic Profile

• Symptoms: Rectal bleeding (50-60%), bowel habit changes (40%), abdominal pain (30%), weight loss (25%)
• Diagnostic Delay: 34-60 days symptom-to-diagnosis; false-negative colonoscopy (2.5-7.7%)
• Ada Surface Ability: 7/10 — GI symptoms well-captured; rectal bleeding is red flag; high false-positive rate (hemorrhoids, IBS)

Commercial Context

• Maturity: CRC indication is mature, lower priority than HNSCC
• Company Motivation: 6/10 — Patient finding can offset biosimilar erosion but limited upside vs other indications

6. OGSIVEO (Nirogacestat) - Desmoid Tumors

Tier 2 | Fit Score: 7/10 | SpringWorks Integration KPI

Key Insight

CEO Priority Asset: Merck acquired SpringWorks for $3.9B (July 2025), making Ogsiveo integration success a critical KPI for CEO Kai Beckmann's first major M&A. Desmoid tumors dismissed as benign lipomas/fibromas for 12-24 months before specialist referral.

Market Numbers

• USA: 900-1,500 annual desmoid cases → 450-900 progressive/symptomatic (Ogsiveo-eligible) → 20% delay = 90-180 undiagnosed
• Rarity: 2.7-4.5 per million incidence; often associated with FAP (familial adenomatous polyposis)
• Revenue: Ogsiveo $172M (2024); analyst peak >$1B by 2030

Clinical & Diagnostic Profile

• Symptoms: Slowly growing, painless/mildly painful mass (80%), firm, fixed; locations: abdomen (45%), extremities (30%), chest wall (15%)
• Diagnostic Delay: 12-24 months (estimated); dismissed as benign fibroma, requires sarcoma specialist not general surgery
• Ada Surface Ability: 6/10 — Mass detection via self-report; risk factors (FAP, prior surgery) help; requires imaging/specialist

Strategic Value

• Company Motivation: 9/10 — HIGHEST strategic priority as newest acquisition; launch excellence critical
• Opportunity: Early integrator advantage (Ada partnership as part of launch excellence); partnership with FAP patient registries creates durable referral channels

NOT SUITABLE: MAVENCLAD (Cladribine) - Multiple Sclerosis

Tier: NO | Fit Score: 4/10 | Generic Entry Eliminated Economics

Rationale: US generic entry (March 2026) collapsed per-patient revenue from $32,400 to $5,000-$10,000, reducing PF fees to $400-$1,200—insufficient to justify Patient Finder program. While international markets (EU, Asia) retain exclusivity through 2027-2028, the 12-24 month window is too short for Ada program development and scale.

Pre-Generic Potential (Historical Reference): 1,200 undiagnosed drug-addressable patients annually (USA); 40% initial misdiagnosis, median 1-2 year delay. Ada surface ability was 6/10 (MS symptoms detectable but non-specific).

Recommendation: DO NOT PURSUE for Mavenclad. Monitor for re-engagement if Merck develops next-gen cladribine formulation with new patents.

NOT SUITABLE: GONAL-F (Follitropin Alfa) - Fertility

Tier: NO | Fit Score: 2/10 | No Diagnostic Delay Dynamic

Rationale: Fertility treatment has no diagnostic delay or underdiagnosis issue. Patients actively seek care after 12 months of unsuccessful conception. The barrier is ACCESS (cost, insurance coverage, clinic availability), not patient identification.

Market Context: Gonal-f revenue ~$1.4-1.6B (2024), market leader in fertility; biosimilars eroding pricing in EU. Ada Patient Finder model does not apply—patients self-identify as infertile.

Recommendation: DO NOT PURSUE for Gonal-f or fertility portfolio. Focus: Access programs and biosimilar defense, not patient finding.